Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19133467 | 0.98 | IDO1 (0.44) | IDO1MAPTPOLBHPGDHTT | |
| SCHEMBL12348320 | 0.84 | IDO1 (0.32) | IDO1MAPTPOLBHPGDHTT | |
| SCHEMBL5350091 | 0.83 | KMT2A (0.40) | IDO1MAPTPOLBHPGDHTT | |
| SCHEMBL14317086 | 0.81 | KMT2A (0.42) | IDO1MAPTPOLBHPGDHTT | |
| SCHEMBL179219 | 0.77 | — | — | |
| SCHEMBL12053623 | 0.74 | POLB (0.51) | IDO1MAPTPOLBHPGDHTT | |
| SCHEMBL14964571 | 0.74 | — | — | |
| SCHEMBL12054248 | 0.73 | IDO1 (0.55) | IDO1MAPTPOLBHPGDHTT | |
| SCHEMBL179213 | 0.73 | — | — | |
| SCHEMBL5041807 | 0.72 | KMT2A (0.42) | IDO1MAPTPOLBHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389783-B1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE HOLDINGS CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| EP-2911669-B1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | UNIV CHICAGO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-109897011-B | IDO inhibitor and application thereof | 上海华汇拓医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3600299-B1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220331296-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2022-10-20 | — | — | US | disclosed |
| WO-2022167819-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | disclosed |
| WO-2010005958-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-1879573-A4 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1879573-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | disclosed |
| WO-2006122150-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1660467-A2 | AMINOFURAZAN COMPOUNDS AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005019190-A2 | (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885MAPT 3215/4885POLB 2730/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885MAPT 3215/4885POLB 2730/4885 |
| US-20240158385-A1 | NOVEL COMPOUNDS | KCNK3, KCNA4, KCNK13 | IDO1 3146/4885MAPT 4204/4885POLB 4346/4885 |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | PHKG1, MAP3K20, MAP3K5 | IDO1 2426/4885MAPT 1028/4885POLB 2199/4885 |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885MAPT 3215/4885POLB 2730/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885MAPT 3106/4885POLB 3727/4885 |
| US-20220331296-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885MAPT 3215/4885POLB 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.